6-MAPB

Chemical compound From Wikipedia, the free encyclopedia

6-MAPB (1-(benzofuran-6-yl)-N-methylpropan-2-amine) is an entactogen of the benzofuran family which is structurally related to 6-APB and MDMA.[1][2][3][4][5] It is known to be a serotonin releasing agent and, unlike MDMA, a potent serotonin 5-HT1B receptor agonist.[6] The drug is not known to have been widely sold as a "designer drug" but has been detected in analytical samples taken from individuals hospitalised after using drug combinations that included other benzofuran derivatives.[citation needed] 6-MAPB was first encountered as a novel designer drug in 2013 and described in the scientific literature in 2014.[7][8] It was banned in the United Kingdom in June 2013, along with 9 other related compounds which were thought to produce similar effects.[9]

Other names1-(Benzofuran-6-yl)-N-methylpropan-2-amine
Legal status
Quick facts Clinical data, Other names ...
6-MAPB
Clinical data
Other names1-(Benzofuran-6-yl)-N-methylpropan-2-amine
Routes of
administration
Oral[1]
Drug classMonoamine releasing agent; Serotonin 5-HT1B receptor agonist
Legal status
Legal status
Pharmacokinetic data
Duration of action6–8 hours[1]
Identifiers
  • 1-(Benzofuran-6-yl)-N-methylpropan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H15NO
Molar mass189.258 g·mol−1
3D model (JSmol)
  • CC(NC)CC1=CC(OC=C2)=C2C=C1
  • InChI=1S/C12H15NO/c1-9(13-2)7-10-3-4-11-5-6-14-12(11)8-10/h3-6,8-9,13H,7H2,1-2H3
  • Key:QLAAURQYEAEHBO-UHFFFAOYSA-N
Close

Interactions

See also

References

Related Articles

Wikiwand AI